An 83-year-old female patient received gefitinib 0.25 g once daily due to right lung adenocarcinoma with left lung metastasis and suspicious liver metastasis. She developed severe diarrhea with nausea and vomiting 27 days after treatment. Laboratory test showed that blood potassium was 2.1 mmol/L. The results of fecal culture were negative, and infectious diarrhea was excluded. Gefinib was continued. After 4 days of treatments with potassium supplement and antidiarrheal, the patient recovered. Four days later, the patient developed the above symptoms again, and the laboratory test showed that the blood potassium was 2.96 mmol/L. Diarrhea and hypokalemia were considered to be related to gefitinib. The drug was withdrawn and the symptomatic treatments such as potassium supplement, antidiarrheal, antiemetic, and stomach protection were given. Nine days of drug withdrawal, her symptoms of diarrhea, nausea, and vomiting were relieved, and laboratory test showed that blood potassium was 3.52 mmol/L; 22 days of drug withdrawal, the diarrhea, nausea, and vomiting disappeared, and the laboratory test showed that blood potassium was 4.69 mmol/L.

An 83-year-old female patient received gefitinib 0.25 g once daily due to right lung adenocarcinoma with left lung metastasis and suspicious liver metastasis. She developed severe diarrhea with nausea and vomiting 27 days after treatment. Laboratory test showed that blood potassium was 2.1 mmol/L. The results of fecal culture were negative, and infectious diarrhea was excluded. Gefinib was continued. After 4 days of treatments with potassium supplement and antidiarrheal, the patient recovered. Four days later, the patient developed the above symptoms again, and the laboratory test showed that the blood potassium was 2.96 mmol/L. Diarrhea and hypokalemia were considered to be related to gefitinib. The drug was withdrawn and the symptomatic treatments such as potassium supplement, antidiarrheal, antiemetic, and stomach protection were given. Nine days of drug withdrawal, her symptoms of diarrhea, nausea, and vomiting were relieved, and laboratory test showed that blood potassium was 3.52 mmol/L; 22 days of drug withdrawal, the diarrhea, nausea, and vomiting disappeared, and the laboratory test showed that blood potassium was 4.69 mmol/L.

A 54-year-old female patient was scheduled to undergo laparoscopic segmental resection for hepatic hemangioma. Thirty minutes before operation, an IV infusion of etimicin sulfate and sodium chloride injection 100 mg was given to prevent infection. After 2 minutes of medication, the patient developed general numbness, apathy, redness of the skin, cold sweating, and dyspnea. Her breath rate was 22 times per minute, heart rate was 110 beats per minute, blood pressure was 45/32 mmHg, and pulse oxygen saturation (SPO 2) was undetectable. Anaphylactic shock due to etimicin was considered. Etimicin was discontinued immediately and treatments such as oxygen inhalation, epinephrine, methylprednisolone sodium succinate, norepinephrine, and intravenous volume expansion were administered. Twenty minutes later, the patient′s symptoms were basically relieved, with breath rate 18 times per minute, heart rate 88 times per minute, blood pressure 108/60 mmHg, and SPO 2 0.99. Thirteen hours later, all symptoms disappeared.

A 54-year-old female patient was scheduled to undergo laparoscopic segmental resection for hepatic hemangioma. Thirty minutes before operation, an IV infusion of etimicin sulfate and sodium chloride injection 100 mg was given to prevent infection. After 2 minutes of medication, the patient developed general numbness, apathy, redness of the skin, cold sweating, and dyspnea. Her breath rate was 22 times per minute, heart rate was 110 beats per minute, blood pressure was 45/32 mmHg, and pulse oxygen saturation (SPO 2) was undetectable. Anaphylactic shock due to etimicin was considered. Etimicin was discontinued immediately and treatments such as oxygen inhalation, epinephrine, methylprednisolone sodium succinate, norepinephrine, and intravenous volume expansion were administered. Twenty minutes later, the patient′s symptoms were basically relieved, with breath rate 18 times per minute, heart rate 88 times per minute, blood pressure 108/60 mmHg, and SPO 2 0.99. Thirteen hours later, all symptoms disappeared.

A 64-year-old male patient with colon cancer received one cycle chemotherapy of oxaliplatin+capecitabine and 7 cycles of oxaliplatin+raltitrexed chemotherapy. There were no interstitial changes in chest CT before operation. After 8 cycles of chemotherapy, the patient developed chest tightness and shortness of breath. Chest CT showed interstitial changes in bilateral lungs, which were considered to be related to oxaliplatin. After 31 days of treatments with drugs such as broad-spectrum antibiotics, glucocorticoids, acetylcysteine, and reduced glutathione, as well as noninvasive ventilator assisted ventilation, oxygen inhalation, and other symptomatic treatments, his symptoms of chest tightness and shortness of breath were relieved, and chest CT showed that interstitial lesions in the bilateral lungs were obviously relieved.

A 64-year-old male patient with colon cancer received one cycle chemotherapy of oxaliplatin+capecitabine and 7 cycles of oxaliplatin+raltitrexed chemotherapy. There were no interstitial changes in chest CT before operation. After 8 cycles of chemotherapy, the patient developed chest tightness and shortness of breath. Chest CT showed interstitial changes in bilateral lungs, which were considered to be related to oxaliplatin. After 31 days of treatments with drugs such as broad-spectrum antibiotics, glucocorticoids, acetylcysteine, and reduced glutathione, as well as noninvasive ventilator assisted ventilation, oxygen inhalation, and other symptomatic treatments, his symptoms of chest tightness and shortness of breath were relieved, and chest CT showed that interstitial lesions in the bilateral lungs were obviously relieved.